Recombinant soluble TRAIL exhibits strong tumoricidal activity against GBM cells with no or minimal toxicity against normal cells.5 However, recent studies indicate that no single therapeutic agent, including TRAIL, is likely to be effective enough.3, 6 Therefore, the anti-GBM activity of TRAIL, an ideal candidate for combinatorial strategies, was combined with a variety of conventional or novel targeted therapies to achieve synergistic enhancement of TRAIL activity.5, 6. The gene discussed is TNFSF10; the disease is glioblastoma.